The relatively recent understanding that tumors avoid elimination by promoting inhibitory receptor signaling by tumor-specific CD8+ T cells has led to remarkable, but limited, success in the treatment of certain cancers through the use of checkpoint blockade therapies. This evidence concerns the gene CD8A and neoplasm.